Hormonal
Discontinuing or interrupting GLP-1 receptor agonist (GLP-1RA) treatment progressively erodes cardiovascular protection, with longer durations of non-use associated with a graded increase in the risk of major adverse cardiovascular events (MACE).
If you have Type 2 Diabetes and take a GLP-1RA (like Ozempic or Wegovy), your heart protection is tied to continuous use. Stopping the medication does not leave you in a 'safe' state; it actively increases your risk of heart attack or stroke, and the longer you stay off the drug, the higher that risk becomes. If you must stop due to side effects or cost, do not just stop abruptly; consult your provider for a strategy to manage the increased cardiovascular risk during the transition.
Discontinuations diminished the cardiovascular effectiveness of GLP- 1RAs, with longer durations of discontinuation associated with greater loss in effectiveness
Why this rating
Large-scale target trial emulation with rigorous statistical weighting (marginal structural models) in a real-world population.
Source
Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation
Yan Xie et al. · BMJ Medicine · 2026
DOI 10.1136/bmjmed-2025-002150
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →